This study will evaluate the efficacy and safety of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
247
Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
Placebo, Dose B; dose applied to the lateral canthal lines
Dermatology Research Institute
Coral Gables, Florida, United States
Composite endpoint based upon the investigator global assessment and patient assessment of severity of lateral canthal lines
Time frame: Week 4
Proportion of subjects with 2 point or greater improvement from baseline using the Investigator Global Assessment
Time frame: Week 4
Proportion of subjects with 1 point or greater improvement from baseline using the Investigator Global Assessment
Time frame: Week 4
Proportion of subjects with a 2 point or greater improvement from baseline using the Patient Severity Assessment
Time frame: Week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.